Hyperthermic intraperitoneal chemotherapy in ovarian cancer first report of the HYPER-O registry

Cyril William Helm, Scott D. Richard, Jianmin Pan, David Bartlett, Martin D. Goodman, Rick Hoefer, Sam S. Lentz, Edward A. Levine, Brian W. Loggie, Daniel S. Metzinger, Brigitte Miller, Lynn Parker, James E. Spellman, Paul H. Sugarbaker, Robert P. Edwards, Shesh N. Rai

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Introduction: An analysis of experience of surgical and gynecologic oncologists in the United States with the use of hyperthermic intraperitoneal chemotherapy for women with invasive epithelial ovarian cancer (EOC). Methods: An Internet-based registry (HYPER-O) collected data from collaborating institutions. Eligibility included women with EOC treated with hyperthermic intraperitoneal chemotherapy. Borderline and nonepithelial cancers were excluded. Results: As of July 1, 2008, 141 women were eligible for analysis treated at the following time points: frontline (n = 26), interval debulking (n = 19), consolidation (n = 12), and recurrence (n = 83). The mean perfusion temperatures were 38.5 to 43.6°C (median, 41.9°C) for inflow and 36.9 to 42.9°C (median, 41°C) for outflow for 30 to 120 minutes. Treatment was with a platinum agent (n = 72), mitomycin (n = 53), or a combination (n = 14). Median follow-up was 18 months (range, 0.3-140.5 months) and median overall survival 30.3 months (95% confidence interval, 23.0-37.6) with 2-, 5-, and 10-year overall survival probabilities of 49.1%, 25.4%, and 14.3%, respectively. Of the 141 patients, 110 (78%) experienced recurrence of ovarian cancer and 87 died, 3 (0.5%) dying within 30 days of surgery. In the multivariable analysis, the factors significant for increased survival were sensitivity to platinum response (P = 0.048), completeness of cytoreduction scores of 1 or 0 (P = 0.025), carboplatin alone or a combination of 2 or more chemotherapy agents used (P = 0.011), and duration of hospital stays of 10 days or less (P = 0.021). Conclusions: Hyperthermic intraperitoneal chemotherapy is a viable additional treatment option for patients with invasive EOC and may extend life in selected groups. It warrants further study in randomized controlled trials.

Original languageEnglish
Pages (from-to)61-69
Number of pages9
JournalInternational Journal of Gynecological Cancer
Volume20
Issue number1
DOIs
StatePublished - Jan 2010

Fingerprint

Ovarian Neoplasms
Registries
Drug Therapy
Platinum
Survival
Recurrence
Carboplatin
Mitomycin
Ambulatory Surgical Procedures
Internet
Length of Stay
Randomized Controlled Trials
Perfusion
Confidence Intervals
Temperature
Therapeutics
Ovarian epithelial cancer
Neoplasms

All Science Journal Classification (ASJC) codes

  • Obstetrics and Gynecology
  • Oncology

Cite this

Hyperthermic intraperitoneal chemotherapy in ovarian cancer first report of the HYPER-O registry. / Helm, Cyril William; Richard, Scott D.; Pan, Jianmin; Bartlett, David; Goodman, Martin D.; Hoefer, Rick; Lentz, Sam S.; Levine, Edward A.; Loggie, Brian W.; Metzinger, Daniel S.; Miller, Brigitte; Parker, Lynn; Spellman, James E.; Sugarbaker, Paul H.; Edwards, Robert P.; Rai, Shesh N.

In: International Journal of Gynecological Cancer, Vol. 20, No. 1, 01.2010, p. 61-69.

Research output: Contribution to journalArticle

Helm, CW, Richard, SD, Pan, J, Bartlett, D, Goodman, MD, Hoefer, R, Lentz, SS, Levine, EA, Loggie, BW, Metzinger, DS, Miller, B, Parker, L, Spellman, JE, Sugarbaker, PH, Edwards, RP & Rai, SN 2010, 'Hyperthermic intraperitoneal chemotherapy in ovarian cancer first report of the HYPER-O registry', International Journal of Gynecological Cancer, vol. 20, no. 1, pp. 61-69. https://doi.org/10.1111/IGC.0b013e3181c50cde
Helm, Cyril William ; Richard, Scott D. ; Pan, Jianmin ; Bartlett, David ; Goodman, Martin D. ; Hoefer, Rick ; Lentz, Sam S. ; Levine, Edward A. ; Loggie, Brian W. ; Metzinger, Daniel S. ; Miller, Brigitte ; Parker, Lynn ; Spellman, James E. ; Sugarbaker, Paul H. ; Edwards, Robert P. ; Rai, Shesh N. / Hyperthermic intraperitoneal chemotherapy in ovarian cancer first report of the HYPER-O registry. In: International Journal of Gynecological Cancer. 2010 ; Vol. 20, No. 1. pp. 61-69.
@article{bdd3f566483c45048303891e284476df,
title = "Hyperthermic intraperitoneal chemotherapy in ovarian cancer first report of the HYPER-O registry",
abstract = "Introduction: An analysis of experience of surgical and gynecologic oncologists in the United States with the use of hyperthermic intraperitoneal chemotherapy for women with invasive epithelial ovarian cancer (EOC). Methods: An Internet-based registry (HYPER-O) collected data from collaborating institutions. Eligibility included women with EOC treated with hyperthermic intraperitoneal chemotherapy. Borderline and nonepithelial cancers were excluded. Results: As of July 1, 2008, 141 women were eligible for analysis treated at the following time points: frontline (n = 26), interval debulking (n = 19), consolidation (n = 12), and recurrence (n = 83). The mean perfusion temperatures were 38.5 to 43.6°C (median, 41.9°C) for inflow and 36.9 to 42.9°C (median, 41°C) for outflow for 30 to 120 minutes. Treatment was with a platinum agent (n = 72), mitomycin (n = 53), or a combination (n = 14). Median follow-up was 18 months (range, 0.3-140.5 months) and median overall survival 30.3 months (95{\%} confidence interval, 23.0-37.6) with 2-, 5-, and 10-year overall survival probabilities of 49.1{\%}, 25.4{\%}, and 14.3{\%}, respectively. Of the 141 patients, 110 (78{\%}) experienced recurrence of ovarian cancer and 87 died, 3 (0.5{\%}) dying within 30 days of surgery. In the multivariable analysis, the factors significant for increased survival were sensitivity to platinum response (P = 0.048), completeness of cytoreduction scores of 1 or 0 (P = 0.025), carboplatin alone or a combination of 2 or more chemotherapy agents used (P = 0.011), and duration of hospital stays of 10 days or less (P = 0.021). Conclusions: Hyperthermic intraperitoneal chemotherapy is a viable additional treatment option for patients with invasive EOC and may extend life in selected groups. It warrants further study in randomized controlled trials.",
author = "Helm, {Cyril William} and Richard, {Scott D.} and Jianmin Pan and David Bartlett and Goodman, {Martin D.} and Rick Hoefer and Lentz, {Sam S.} and Levine, {Edward A.} and Loggie, {Brian W.} and Metzinger, {Daniel S.} and Brigitte Miller and Lynn Parker and Spellman, {James E.} and Sugarbaker, {Paul H.} and Edwards, {Robert P.} and Rai, {Shesh N.}",
year = "2010",
month = "1",
doi = "10.1111/IGC.0b013e3181c50cde",
language = "English",
volume = "20",
pages = "61--69",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Hyperthermic intraperitoneal chemotherapy in ovarian cancer first report of the HYPER-O registry

AU - Helm, Cyril William

AU - Richard, Scott D.

AU - Pan, Jianmin

AU - Bartlett, David

AU - Goodman, Martin D.

AU - Hoefer, Rick

AU - Lentz, Sam S.

AU - Levine, Edward A.

AU - Loggie, Brian W.

AU - Metzinger, Daniel S.

AU - Miller, Brigitte

AU - Parker, Lynn

AU - Spellman, James E.

AU - Sugarbaker, Paul H.

AU - Edwards, Robert P.

AU - Rai, Shesh N.

PY - 2010/1

Y1 - 2010/1

N2 - Introduction: An analysis of experience of surgical and gynecologic oncologists in the United States with the use of hyperthermic intraperitoneal chemotherapy for women with invasive epithelial ovarian cancer (EOC). Methods: An Internet-based registry (HYPER-O) collected data from collaborating institutions. Eligibility included women with EOC treated with hyperthermic intraperitoneal chemotherapy. Borderline and nonepithelial cancers were excluded. Results: As of July 1, 2008, 141 women were eligible for analysis treated at the following time points: frontline (n = 26), interval debulking (n = 19), consolidation (n = 12), and recurrence (n = 83). The mean perfusion temperatures were 38.5 to 43.6°C (median, 41.9°C) for inflow and 36.9 to 42.9°C (median, 41°C) for outflow for 30 to 120 minutes. Treatment was with a platinum agent (n = 72), mitomycin (n = 53), or a combination (n = 14). Median follow-up was 18 months (range, 0.3-140.5 months) and median overall survival 30.3 months (95% confidence interval, 23.0-37.6) with 2-, 5-, and 10-year overall survival probabilities of 49.1%, 25.4%, and 14.3%, respectively. Of the 141 patients, 110 (78%) experienced recurrence of ovarian cancer and 87 died, 3 (0.5%) dying within 30 days of surgery. In the multivariable analysis, the factors significant for increased survival were sensitivity to platinum response (P = 0.048), completeness of cytoreduction scores of 1 or 0 (P = 0.025), carboplatin alone or a combination of 2 or more chemotherapy agents used (P = 0.011), and duration of hospital stays of 10 days or less (P = 0.021). Conclusions: Hyperthermic intraperitoneal chemotherapy is a viable additional treatment option for patients with invasive EOC and may extend life in selected groups. It warrants further study in randomized controlled trials.

AB - Introduction: An analysis of experience of surgical and gynecologic oncologists in the United States with the use of hyperthermic intraperitoneal chemotherapy for women with invasive epithelial ovarian cancer (EOC). Methods: An Internet-based registry (HYPER-O) collected data from collaborating institutions. Eligibility included women with EOC treated with hyperthermic intraperitoneal chemotherapy. Borderline and nonepithelial cancers were excluded. Results: As of July 1, 2008, 141 women were eligible for analysis treated at the following time points: frontline (n = 26), interval debulking (n = 19), consolidation (n = 12), and recurrence (n = 83). The mean perfusion temperatures were 38.5 to 43.6°C (median, 41.9°C) for inflow and 36.9 to 42.9°C (median, 41°C) for outflow for 30 to 120 minutes. Treatment was with a platinum agent (n = 72), mitomycin (n = 53), or a combination (n = 14). Median follow-up was 18 months (range, 0.3-140.5 months) and median overall survival 30.3 months (95% confidence interval, 23.0-37.6) with 2-, 5-, and 10-year overall survival probabilities of 49.1%, 25.4%, and 14.3%, respectively. Of the 141 patients, 110 (78%) experienced recurrence of ovarian cancer and 87 died, 3 (0.5%) dying within 30 days of surgery. In the multivariable analysis, the factors significant for increased survival were sensitivity to platinum response (P = 0.048), completeness of cytoreduction scores of 1 or 0 (P = 0.025), carboplatin alone or a combination of 2 or more chemotherapy agents used (P = 0.011), and duration of hospital stays of 10 days or less (P = 0.021). Conclusions: Hyperthermic intraperitoneal chemotherapy is a viable additional treatment option for patients with invasive EOC and may extend life in selected groups. It warrants further study in randomized controlled trials.

UR - http://www.scopus.com/inward/record.url?scp=74249089375&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74249089375&partnerID=8YFLogxK

U2 - 10.1111/IGC.0b013e3181c50cde

DO - 10.1111/IGC.0b013e3181c50cde

M3 - Article

VL - 20

SP - 61

EP - 69

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 1

ER -